LGI1 antibody [N2C2], Internal
Not tested in other applications.
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||64 kDa (note)
|Positive Controls||293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Full Name||leucine-rich, glioma inactivated 1|
|Product Description||Rabbit polyclonal antibody to LGI1 (leucine-rich, glioma inactivated 1)|
|Background||This gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas. Mutations in this gene result in autosomal dominant lateral temporal epilepsy. [provided by RefSeq]|
|Synonyms||EPITEMPIN antibody, EPT antibody, ETL1 antibody, IB1099 antibody, LGI1 antibody, epitempin-1 antibody, leucine-rich glioma-inactivated protein 1 antibody, "leucine-rich, glioma inactivated 1 antibody"|
|Immunogen||Recombinant protein encompassing a sequence within the center region of human LGI1. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Mouse, Rat, Chicken, Rhesus Monkey, Chimpanzee, Bovine|
|Predict Reactivity Note||Mouse (95%), Rat (95%), Chicken (86%), Rhesus Monkey (100%), Chimpanzee (100%), Bovine (98%)|